USFDA11 Oct 2025, 12:24 pm
Lupin Ltd Receives One Observation from U.S. FDA in Pre-Approval Inspection at Somerset Facility
AI Summary
Lupin Ltd, a prominent pharmaceutical company, has recently undergone a Pre-Approval Inspection by the U.S. Food and Drug Administration (FDA) at its manufacturing facility in Somerset, New Jersey, USA. The inspection took place from September 29 to October 10, 2025, and resulted in one observation. The company has committed to addressing this observation and responding to the U.S. FDA within the specified timeframe. Lupin is dedicated to maintaining compliance with Current Good Manufacturing Practice (CGMP) standards across all its facilities.
Key Highlights
- Lupin Ltd underwent a Pre-Approval Inspection by the U.S. FDA at its Somerset facility
- The inspection occurred from September 29 to October 10, 2025
- One observation was issued by the U.S. FDA during the inspection
- Lupin is committed to addressing the observation and responding to the U.S. FDA within the stipulated timeframe
- The company is dedicated to maintaining CGMP compliance across all its facilities